| Keywords: |
cancer chemotherapy; treatment response; gene translocation; clinical trial; disease course; fatigue; neutropenia; review; interferon; ascites; diarrhea; treatment duration; antineoplastic agents; antineoplastic agent; imatinib; edema; liver toxicity; anemia; gastrointestinal symptom; nausea; thrombocytopenia; qt prolongation; cytogenetics; nccn clinical practice guidelines; dexamethasone; practice guideline; hematopoietic stem cell transplantation; dasatinib; chronic myeloid leukemia; transplantation; rash; depression; drug antagonism; phenobarbital; paracetamol; warfarin; pleura effusion; therapy effect; food drug interaction; headache; hematopoietic stem cell; clarithromycin; ketoconazole; nilotinib; pericardial effusion; rifampicin; karyotyping; leukemia, myelogenous, chronic, bcr-abl positive; simvastatin; cyclosporin; phenytoin; hypericum perforatum; allogenic hsct; chronic myelogenous leukemia; cytogenetic response; hematologic response; aprepitant; carbamazepine; erythromycin; itraconazole; pimozide; rifabutin; rifapentine; grapefruit juice; muscle cramp; philadelphia 1 chromosome
|
